CClinicalTrials.gg
CompletedNCT03171428Updated Jun 1, 2017

Hepatectomy With or Without the Thoraco-abdominal Approach

An observational study in Surgery, Liver Tumors and Hepatectomy, sponsored by University of Milan. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-01.

Sponsored by University of Milan · Observational

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
744
Ages
18 Years and older
Sex
All
01

Study summary

The performance of hepatectomy for liver tumors using the thoraco-abdominal approach (TAA) versus the abdominal approach (AA) is still debated.

The aim of the study is the analysis of the perioperative outcome of patients operated with or without the TAA for liver tumors.

Read the detailed description

The prospectively maintained database was queried. A 1:1 propensity score-matched analysis was applied. Among 744 patients, 246 undergoing hepatectomy with TAA and 246 undergoing hepatectomy with AA were compared. These patients were matched for baseline characteristics, underlying liver disease, comorbidity, tumor features, and extent of the resection. The rates of morbidity and mortality were the study endpoints.

02

Conditions studied

  • Surgery
  • Liver Tumors
  • Hepatectomy
  • Liver Resection

Browse trials for

03

In context

Liver Neoplasms

1,391 studies on the registry are indexed under Liver Neoplasms; 345 are open to participants now.

This study's enrollment of 744 is above the median of 200 across 350 observational studies indexed under Liver Neoplasms.

Browse Liver Neoplasms studies →

Lead sponsor

University of Milan is the lead sponsor of 177 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients affected by liver tumors scheduled for hepatectomy at our center.

Inclusion criteria

  • First liver surgery;
  • Any type of malignant liver tumor, including hepatocellular carcinoma on cirrhosis.

Exclusion criteria

Exclusion Criteria:

  • Previous history of liver surgery;
  • Any type of benign liver tumor;
  • Incomplete clinical, surgical, pathological or postoperative data;
  • Patients treated with radiofrequency ablation alone or in combination with surgery were also excluded.
05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
744 participants (actual)
Patient registry
No

Groups and cohorts

  • TAA

    Thoraco-Abdominal Approach: those patients with liver tumors operated with the thoracic-abdominal approach

    Procedure: Hepatectomy

  • AA

    Abdominal Approach: those patients with liver tumors operated with the abdominal approach (without the thoracotomy)

    Procedure: Hepatectomy

Interventions

  • ProcedureHepatectomy

    Surgery for liver tumors is the removal of a part of the liver affected by a tumor.

    Also known as: hepatic resection; liver resection; liver surgery

06

What researchers measure

Primary outcomes

  1. Short-term outcome: Occurrence of postoperative complications or death after surgery

    Occurrence of postoperative complications or death after surgery

    Time frame: Within 90-days after the operation

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03171428
Lead sponsor
University of Milan
Responsible party
Prof. Guido Torzilli (Director of the Department of Hepatobiliary Surgery, University of Milan) — Principal investigator
First posted
May 31, 2017
Start date
Jan 1, 2007
Primary completion
Dec 31, 2013
Completion
Apr 1, 2015
Last update
Jun 1, 2017

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion